Ferdinando Calabria1, Giuseppe Lucio Cascini. 1. Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, IBFM CNR, Viale Europa, 88100, Germaneto, Catanzaro, Italy. ferdinandocalabria@hotmail.it.
Abstract
UNLABELLED: Considering the intrinsic limits of fluorine-18-dfluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for diagnosing brain tumors and tumor recurrence, several radiopharmaceuticals have been developed to detect brain tumor recurrence after treatment. Among others, a promising tracer is fluorine-18-desoxyphenylalanine (DOPA), due to its very low rate of physiological distribution in normal brain structures of white and grey matter. The aim of our study was to assess the feasibility of PET/CT with (18)F-DOPA in the detection of brain tumor recurrence after treatment, in comparison with MRI performance and other PET radiopharmaceuticals, currently employed in this field. CONCLUSION: The (18)F-DOPA PET/CT seems to be useful in the diagnosis of patients with suspected brain tumor recurrence, because of low signal ratio in normal brain white and grey matter, in particular as compared to (18)F-FDG PET/CT low performance. Related data are presented for other fluorinated amino acid tracers. Magnetic resonance imaging is the gold standard of diagnosis and (18)F-DOPA PET/CT is adjuvant to diagnosis. Further studies are needed to enrich our knowledge about this promising tracer,(18)F-DOPA, especially on its possible role on semi-quantitative measurements in brain tumors.
UNLABELLED: Considering the intrinsic limits of fluorine-18-dfluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for diagnosing brain tumors and tumor recurrence, several radiopharmaceuticals have been developed to detect brain tumor recurrence after treatment. Among others, a promising tracer is fluorine-18-desoxyphenylalanine (DOPA), due to its very low rate of physiological distribution in normal brain structures of white and grey matter. The aim of our study was to assess the feasibility of PET/CT with (18)F-DOPA in the detection of brain tumor recurrence after treatment, in comparison with MRI performance and other PET radiopharmaceuticals, currently employed in this field. CONCLUSION: The (18)F-DOPA PET/CT seems to be useful in the diagnosis of patients with suspected brain tumor recurrence, because of low signal ratio in normal brain white and grey matter, in particular as compared to (18)F-FDG PET/CT low performance. Related data are presented for other fluorinated amino acid tracers. Magnetic resonance imaging is the gold standard of diagnosis and (18)F-DOPA PET/CT is adjuvant to diagnosis. Further studies are needed to enrich our knowledge about this promising tracer,(18)F-DOPA, especially on its possible role on semi-quantitative measurements in brain tumors.
Authors: Andrew V Mossine; Sean S Tanzey; Allen F Brooks; Katarina J Makaravage; Naoko Ichiishi; Jason M Miller; Bradford D Henderson; Marc B Skaddan; Melanie S Sanford; Peter J H Scott Journal: Org Biomol Chem Date: 2019-09-19 Impact factor: 3.876
Authors: Lance T Hall; Benjamin Titz; H Ian Robins; Bryan P Bednarz; Scott B Perlman; Jamey P Weichert; John S Kuo Journal: Am J Nucl Med Mol Imaging Date: 2017-09-01
Authors: Lance T Hall; Benjamin Titz; Nishanta Baidya; Anja G van der Kolk; H Ian Robins; Mario Otto; Scott B Perlman; Jamey P Weichert; John S Kuo Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Andrew V Mossine; Sean S Tanzey; Allen F Brooks; Katarina J Makaravage; Naoko Ichiishi; Jason M Miller; Bradford D Henderson; Thomas Erhard; Christian Bruetting; Marc B Skaddan; Melanie S Sanford; Peter J H Scott Journal: Nat Protoc Date: 2020-04-08 Impact factor: 13.491
Authors: Jay S Wright; Tanpreet Kaur; Sean Preshlock; Sean S Tanzey; Wade P Winton; Liam S Sharninghausen; Nicholas Wiesner; Allen F Brooks; Melanie S Sanford; Peter J H Scott Journal: Clin Transl Imaging Date: 2020-05-26